Core Insights - H.R. 7091 is a bipartisan legislation aimed at expanding research and development for emerging therapies for Alcohol Use Disorder (AUD) among U.S. veterans, recognizing the significant prevalence of AUD in this population [1][2][5] Group 1: Legislative Context - The legislation specifically includes AUD as a condition eligible for expanded research and development, supporting non-abstinence based treatment options [3] - H.R. 7091 aligns with the U.S. Government's updated definition of recovery, which emphasizes harm reduction and reductions in heavy drinking as meaningful clinical outcomes [3][5] Group 2: Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction, with its lead investigational product candidate, AD04, targeting AUD through a genetically targeted therapy approach [4][7] - AD04 follows a non-abstinence based treatment strategy and aims to reduce heavy drinking days, consistent with FDA-supported endpoints [4][6] Group 3: Market Implications - The introduction of H.R. 7091 is seen as a significant step forward for veterans needing additional treatment options for AUD, reflecting bipartisan recognition of the need for innovative approaches to Substance Use Disorders [5][6] - Adial believes that the legislation reinforces federal support for harm reduction-based treatment paradigms, potentially advancing the development of therapies like AD04 [6]